SERA

Financial Results Announcement: Sera Prognostics Inc. will report its third quarter fiscal year 2025 financial results on November 13, 2025, followed by a conference call at 5:00 p.m. ET to discuss the results and operational highlights.

Company Overview: Sera Prognostics focuses on improving maternal and neonatal health through innovative pregnancy biomarker information, with a mission to reduce healthcare costs and improve outcomes for mothers and newborns.

PreTRM® Test Details: The PreTRM® Test is a blood-based biomarker test that predicts the risk of spontaneous preterm birth in asymptomatic singleton pregnancies, allowing for personalized clinical decisions.

Preterm Birth Impact: Preterm birth, occurring before 37 weeks of gestation, is a leading cause of illness and death in newborns, with significant long-term health complications and estimated annual healthcare costs of around $25 billion in the U.S.

New Appointment: Sera Prognostics, Inc. has appointed Tiffany Inglis as Chief Medical Officer to lead clinical operations focused on women's health diagnostics for pregnant women and newborns.

Strategic Goals: Inglis's expertise will support Sera's strategy to enhance payer coverage, update clinical guidelines, and establish the PreTRM Test as the standard of care in the industry.

Appointment of Chief Medical Officer: Sera Prognostics has appointed Dr. Tiffany Inglis as Chief Medical Officer to enhance its clinical operations and leadership in women's health diagnostics, particularly focusing on improving maternal and neonatal health.

Focus on PreTRM® Test: Dr. Inglis will lead efforts to establish the PreTRM® Test as a standard of care, aiming to provide early risk predictions for preterm birth and improve healthcare access and outcomes for pregnant women and newborns.